<?xml version="1.0" encoding="utf-8"?>
<?xml-stylesheet type='text/xsl' href='../../ld2webpage.xsl'?>
<LOBBYINGDISCLOSURE2>
  <imported>Y</imported>
  <pages>10</pages>
  <submitURL>
  </submitURL>
  <organizationName>JOHNSON &amp; JOHNSON SERVICES, INC.</organizationName>
  <prefix>
  </prefix>
  <firstName>
  </firstName>
  <lastName>
  </lastName>
  <registrantDifferentAddress>N</registrantDifferentAddress>
  <address1>ONE JOHNSON &amp; JOHNSON PLAZA</address1>
  <address2>
  </address2>
  <city>NEW BRUNSWICK</city>
  <state>NJ</state>
  <zip>08933</zip>
  <zipext>
  </zipext>
  <country>USA</country>
  <principal_city>
  </principal_city>
  <principal_state>
  </principal_state>
  <principal_zip>
  </principal_zip>
  <principal_zipext>
  </principal_zipext>
  <principal_country>
  </principal_country>
  <contactIntlPhone>
  </contactIntlPhone>
  <selfSelect>Y</selfSelect>
  <clientName>JOHNSON &amp; JOHNSON SERVICES, INC.</clientName>
  <clientGovtEntity>N</clientGovtEntity>
  <senateID>20686-12</senateID>
  <houseID>303480000</houseID>
  <reportYear>2016</reportYear>
  <reportType>Q1</reportType>
  <terminationDate>
  </terminationDate>
  <noLobbying>
  </noLobbying>
  <income>
  </income>
  <expenses>1140000.00</expenses>
  <expensesMethod>A</expensesMethod>
  <printedName>Donald W. Bohn</printedName>
  <signedDate>4/20/2016 4:09:45 PM</signedDate>
  <alis>
    <ali_info>
      <issueAreaCode>TAX</issueAreaCode>
      <specific_issues>
        <description>- HR 1270/S 709, "Restoring Access to Medication Act of 2015", regarding all provisions.
- Issues related to tax reform.  
- Issues related to CFC Look through permanency.
- Issues related to R&amp;D credit.
- Issues related to Mobile Workforce legislation.
- Issues related to Cadillac Tax.
- Issues related to OECD tax reporting.
- Issues related to Repatriation holiday.
- Issues related to Puerto Rico tax treatment.
- Issues related to flexible spending accounts tax treatment.
</description>
      </specific_issues>
      <federal_agencies>U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES</federal_agencies>
      <lobbyists>
        <lobbyist>
          <lobbyistFirstName>David</lobbyistFirstName>
          <lobbyistLastName>Kavanaugh</lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>Darrel</lobbyistFirstName>
          <lobbyistLastName>Jodrey</lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>
          </lobbyistFirstName>
          <lobbyistLastName>
          </lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>
          </lobbyistFirstName>
          <lobbyistLastName>
          </lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>
          </lobbyistFirstName>
          <lobbyistLastName>
          </lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>
          </lobbyistFirstName>
          <lobbyistLastName>
          </lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>
          </lobbyistFirstName>
          <lobbyistLastName>
          </lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>
          </lobbyistFirstName>
          <lobbyistLastName>
          </lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>
          </lobbyistFirstName>
          <lobbyistLastName>
          </lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
      </lobbyists>
      <foreign_entity_issues>
      </foreign_entity_issues>
    </ali_info>
    <ali_info>
      <issueAreaCode>HCR</issueAreaCode>
      <specific_issues>
        <description>- H 2, "Medicare Access and CHIP Reauthorization Act of 2015", regarding all provisions. 
- HR 1078, "Food and Drug Administration Safety Over Sequestration Act of 2015", regarding all provisions. 
- S 1622, "FDA Device Accountability Act of 2015", regarding all provisions. 
- HR 6, "21st Century Cures Act", regarding all provisions.
- S 993, "Comprehensive Justice and Mental Health Act of 2015", regarding all provisions.
- Issues related to physician-owned companies that manufacture or distribute medical devices. 
- Issues relating to cosmetic regulatory reform.
- Issues related to 340B payments to hospitals.
- Issues related to pseudoephedrine. 
- Issues related to dextromethorphan. 
- Issues related to legislation that would modify the Medicare Part B drug reimbursement program.
- Issues related to legislation that would establish a rebate in the Medicare Part D program.
- Issues related to Pub.L. 108-164, "Fairness to Contact Lens Consumers Act" (FCLCA) and related FTC Contact Lens Rule.
- S.2977, "The Medical Electronic Data Technology Enhancement for Consumers' Health" (MEDTECH Act), regarding all provisions.
- H.R. 3250, "DXM Abuse Prevention Act of 2015", regarding all provisions.
- S. 1767, "The Combination Products Regulatory Fairness Act of 2015", regarding all provisions.
- HR 2646, "Helping Families in Mental Health Crisis Act of 2015", regarding all provisions. 
- HR 1854, "Comprehensive Justice and Mental Health Act of 2015", regarding all provisions.
- S. 1014, "Personal Care Products Safety Act", regarding all provisions. 
- S. 277, "Contact lens Consumer Health Protection Act of 2016", regarding all provisions.
- Issues related to Medicare Part B Demo
- Issues related to Expanded Access in Senate Innovation Package</description>
      </specific_issues>
      <federal_agencies>U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES</federal_agencies>
      <lobbyists>
        <lobbyist>
          <lobbyistFirstName>Jane</lobbyistFirstName>
          <lobbyistLastName>Adams</lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>Lauryl</lobbyistFirstName>
          <lobbyistLastName>Jackson</lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>Darrel</lobbyistFirstName>
          <lobbyistLastName>Jodrey</lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>Mark</lobbyistFirstName>
          <lobbyistLastName>Reese</lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>Anne</lobbyistFirstName>
          <lobbyistLastName>Oswalt</lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>Charles</lobbyistFirstName>
          <lobbyistLastName>Nau</lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>Brian</lobbyistFirstName>
          <lobbyistLastName>Burns</lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>Brian</lobbyistFirstName>
          <lobbyistLastName>Kelly</lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>
          </lobbyistFirstName>
          <lobbyistLastName>
          </lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
      </lobbyists>
      <foreign_entity_issues>
      </foreign_entity_issues>
    </ali_info>
    <ali_info>
      <issueAreaCode>ENV</issueAreaCode>
      <specific_issues>
        <description>- HR 1321, "Microbead-Free Waters Act of 2015", regarding all provisions. 
- S 697, "Frank R. Lautenberg Chemical Safety for the 21st Century Act", regarding all provisions. 

</description>
      </specific_issues>
      <federal_agencies>U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES</federal_agencies>
      <lobbyists>
        <lobbyist>
          <lobbyistFirstName>Darrel</lobbyistFirstName>
          <lobbyistLastName>Jodrey</lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>
          </lobbyistFirstName>
          <lobbyistLastName>
          </lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>
          </lobbyistFirstName>
          <lobbyistLastName>
          </lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>
          </lobbyistFirstName>
          <lobbyistLastName>
          </lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>
          </lobbyistFirstName>
          <lobbyistLastName>
          </lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>
          </lobbyistFirstName>
          <lobbyistLastName>
          </lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>
          </lobbyistFirstName>
          <lobbyistLastName>
          </lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>
          </lobbyistFirstName>
          <lobbyistLastName>
          </lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>
          </lobbyistFirstName>
          <lobbyistLastName>
          </lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
      </lobbyists>
      <foreign_entity_issues>
      </foreign_entity_issues>
    </ali_info>
    <ali_info>
      <issueAreaCode>ANI</issueAreaCode>
      <specific_issues>
        <description>- Issues relating to animal testing.
- HR 2858, "Humane Cosmetics Act", regarding all provisions.</description>
      </specific_issues>
      <federal_agencies>U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES</federal_agencies>
      <lobbyists>
        <lobbyist>
          <lobbyistFirstName>Darrel</lobbyistFirstName>
          <lobbyistLastName>Jodrey</lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>
          </lobbyistFirstName>
          <lobbyistLastName>
          </lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>
          </lobbyistFirstName>
          <lobbyistLastName>
          </lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>
          </lobbyistFirstName>
          <lobbyistLastName>
          </lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>
          </lobbyistFirstName>
          <lobbyistLastName>
          </lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>
          </lobbyistFirstName>
          <lobbyistLastName>
          </lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>
          </lobbyistFirstName>
          <lobbyistLastName>
          </lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>
          </lobbyistFirstName>
          <lobbyistLastName>
          </lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>
          </lobbyistFirstName>
          <lobbyistLastName>
          </lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
      </lobbyists>
      <foreign_entity_issues>
      </foreign_entity_issues>
    </ali_info>
    <ali_info>
      <issueAreaCode>BUD</issueAreaCode>
      <specific_issues>
        <description>- HR 83, "Consolidate and Further Continuing Appropriations Act, 2015", provisions related to emergency supplemental funding to address the Ebola epidemic domestically and internationally. 
- Issues related to the funding of the Biomedical Advanced Research and Development Authority.
- FDA Funding.
</description>
      </specific_issues>
      <federal_agencies>U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES</federal_agencies>
      <lobbyists>
        <lobbyist>
          <lobbyistFirstName>Darrel</lobbyistFirstName>
          <lobbyistLastName>Jodrey</lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>Brian</lobbyistFirstName>
          <lobbyistLastName>Burns</lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>Charles</lobbyistFirstName>
          <lobbyistLastName>Nau</lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>
          </lobbyistFirstName>
          <lobbyistLastName>
          </lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>
          </lobbyistFirstName>
          <lobbyistLastName>
          </lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>
          </lobbyistFirstName>
          <lobbyistLastName>
          </lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>
          </lobbyistFirstName>
          <lobbyistLastName>
          </lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>
          </lobbyistFirstName>
          <lobbyistLastName>
          </lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>
          </lobbyistFirstName>
          <lobbyistLastName>
          </lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
      </lobbyists>
      <foreign_entity_issues>
      </foreign_entity_issues>
    </ali_info>
    <ali_info>
      <issueAreaCode>TRD</issueAreaCode>
      <specific_issues>
        <description>- Issues related to Trans-Pacific Partnership agreement.
- Issues related to Transatlantic Trade and Investment Partnership.
- Issues related to the appointment of a dedicated healthcare trade official</description>
      </specific_issues>
      <federal_agencies>U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, U.S. Trade Representative (USTR)</federal_agencies>
      <lobbyists>
        <lobbyist>
          <lobbyistFirstName>David </lobbyistFirstName>
          <lobbyistLastName>Kavanaugh</lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>
          </lobbyistFirstName>
          <lobbyistLastName>
          </lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>
          </lobbyistFirstName>
          <lobbyistLastName>
          </lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>
          </lobbyistFirstName>
          <lobbyistLastName>
          </lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>
          </lobbyistFirstName>
          <lobbyistLastName>
          </lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>
          </lobbyistFirstName>
          <lobbyistLastName>
          </lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>
          </lobbyistFirstName>
          <lobbyistLastName>
          </lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>
          </lobbyistFirstName>
          <lobbyistLastName>
          </lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>
          </lobbyistFirstName>
          <lobbyistLastName>
          </lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
      </lobbyists>
      <foreign_entity_issues>
      </foreign_entity_issues>
    </ali_info>
    <ali_info>
      <issueAreaCode>MMM</issueAreaCode>
      <specific_issues>
        <description>- HR 1427/S 804, "Medicare CGM Access Act of 2015", regarding all provisions. 
- HR 284, "Medicare DMEPOS Competitive Bidding Improvement Act of 2015", regarding all provisions. 
- Issues regarding combination products.
- Issues regarding Transferable Regulatory Exclusivity Incentive.
- Issues related to Expanded Access.
- S. 2736, "Patient Access to Durable Medical Equipment Act of 2016", regarding all provisions.
</description>
      </specific_issues>
      <federal_agencies>U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES</federal_agencies>
      <lobbyists>
        <lobbyist>
          <lobbyistFirstName>Jane</lobbyistFirstName>
          <lobbyistLastName>Adams</lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>Mark</lobbyistFirstName>
          <lobbyistLastName>Reese</lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>Brian</lobbyistFirstName>
          <lobbyistLastName>Kelly</lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>Anne</lobbyistFirstName>
          <lobbyistLastName>Oswalt</lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>Lauryl</lobbyistFirstName>
          <lobbyistLastName>Jackson</lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>
          </lobbyistFirstName>
          <lobbyistLastName>
          </lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>
          </lobbyistFirstName>
          <lobbyistLastName>
          </lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>
          </lobbyistFirstName>
          <lobbyistLastName>
          </lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>
          </lobbyistFirstName>
          <lobbyistLastName>
          </lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
      </lobbyists>
      <foreign_entity_issues>
      </foreign_entity_issues>
    </ali_info>
    <ali_info>
      <issueAreaCode>CPT</issueAreaCode>
      <specific_issues>
        <description>- HR 9, "Goodlatte Innovation Act", regarding all provisions
- S 632, "STRONG Patents Act of 2015", regarding all provisions
- Issues related to the re-introduction of the Patent Abuse Act</description>
      </specific_issues>
      <federal_agencies>U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES</federal_agencies>
      <lobbyists>
        <lobbyist>
          <lobbyistFirstName>Charles</lobbyistFirstName>
          <lobbyistLastName>Nau</lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>
          </lobbyistFirstName>
          <lobbyistLastName>
          </lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>
          </lobbyistFirstName>
          <lobbyistLastName>
          </lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>
          </lobbyistFirstName>
          <lobbyistLastName>
          </lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>
          </lobbyistFirstName>
          <lobbyistLastName>
          </lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>
          </lobbyistFirstName>
          <lobbyistLastName>
          </lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>
          </lobbyistFirstName>
          <lobbyistLastName>
          </lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>
          </lobbyistFirstName>
          <lobbyistLastName>
          </lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>
          </lobbyistFirstName>
          <lobbyistLastName>
          </lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
      </lobbyists>
      <foreign_entity_issues>
      </foreign_entity_issues>
    </ali_info>
  </alis>
  <updates>
    <clientAddress>
    </clientAddress>
    <clientCity>
    </clientCity>
    <clientState>
    </clientState>
    <clientZip>
    </clientZip>
    <clientZipext>
    </clientZipext>
    <clientCountry>
    </clientCountry>
    <prinClientCity>
    </prinClientCity>
    <prinClientState>
    </prinClientState>
    <prinClientZip>
    </prinClientZip>
    <prinClientZipext>
    </prinClientZipext>
    <prinClientCountry>
    </prinClientCountry>
    <generalDescription>
    </generalDescription>
    <inactive_lobbyists>
      <inactive_lobbyist>
        <firstName>
        </firstName>
        <lastName>
        </lastName>
        <suffix>
        </suffix>
      </inactive_lobbyist>
      <inactive_lobbyist>
        <firstName>
        </firstName>
        <lastName>
        </lastName>
        <suffix>
        </suffix>
      </inactive_lobbyist>
      <inactive_lobbyist>
        <firstName>
        </firstName>
        <lastName>
        </lastName>
        <suffix>
        </suffix>
      </inactive_lobbyist>
      <inactive_lobbyist>
        <firstName>
        </firstName>
        <lastName>
        </lastName>
        <suffix>
        </suffix>
      </inactive_lobbyist>
    </inactive_lobbyists>
    <inactive_ALIs>
      <ali_Code>
      </ali_Code>
      <ali_Code>
      </ali_Code>
      <ali_Code>
      </ali_Code>
      <ali_Code>
      </ali_Code>
      <ali_Code>
      </ali_Code>
      <ali_Code>
      </ali_Code>
      <ali_Code>
      </ali_Code>
      <ali_Code>
      </ali_Code>
      <ali_Code>
      </ali_Code>
    </inactive_ALIs>
    <affiliatedUrl>
    </affiliatedUrl>
    <affiliatedOrgs>
      <affiliatedOrg>
        <affiliatedOrgName>
        </affiliatedOrgName>
        <affiliatedOrgAddress>
        </affiliatedOrgAddress>
        <affiliatedOrgCity>
        </affiliatedOrgCity>
        <affiliatedOrgState>
        </affiliatedOrgState>
        <affiliatedOrgZip>
        </affiliatedOrgZip>
        <affiliatedOrgCountry>
        </affiliatedOrgCountry>
        <affiliatedPrinOrgCity>
        </affiliatedPrinOrgCity>
        <affiliatedPrinOrgState>
        </affiliatedPrinOrgState>
        <affiliatedPrinOrgCountry>
        </affiliatedPrinOrgCountry>
      </affiliatedOrg>
      <affiliatedOrg>
        <affiliatedOrgName>
        </affiliatedOrgName>
        <affiliatedOrgAddress>
        </affiliatedOrgAddress>
        <affiliatedOrgCity>
        </affiliatedOrgCity>
        <affiliatedOrgState>
        </affiliatedOrgState>
        <affiliatedOrgZip>
        </affiliatedOrgZip>
        <affiliatedOrgCountry>
        </affiliatedOrgCountry>
        <affiliatedPrinOrgCity>
        </affiliatedPrinOrgCity>
        <affiliatedPrinOrgState>
        </affiliatedPrinOrgState>
        <affiliatedPrinOrgCountry>
        </affiliatedPrinOrgCountry>
      </affiliatedOrg>
    </affiliatedOrgs>
    <inactiveOrgs>
      <inactiveOrgName>
      </inactiveOrgName>
      <inactiveOrgName>
      </inactiveOrgName>
      <inactiveOrgName>
      </inactiveOrgName>
    </inactiveOrgs>
    <foreignEntities>
      <foreignEntity>
        <name>
        </name>
        <address>
        </address>
        <city>
        </city>
        <state>
        </state>
        <country>
        </country>
        <prinCity>
        </prinCity>
        <prinState>
        </prinState>
        <prinCountry>
        </prinCountry>
        <contribution>
        </contribution>
        <ownership_Percentage>
        </ownership_Percentage>
      </foreignEntity>
    </foreignEntities>
    <inactive_ForeignEntities>
      <inactive_ForeignEntity>
      </inactive_ForeignEntity>
      <inactive_ForeignEntity>
      </inactive_ForeignEntity>
      <inactive_ForeignEntity>
      </inactive_ForeignEntity>
      <inactive_ForeignEntity>
      </inactive_ForeignEntity>
      <inactive_ForeignEntity>
      </inactive_ForeignEntity>
      <inactive_ForeignEntity>
      </inactive_ForeignEntity>
    </inactive_ForeignEntities>
  </updates>
</LOBBYINGDISCLOSURE2>